Post-CAR-T Checkpoint Inhibition Can Result in Durable Responses in a Minority of Patients with Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL): Results of a Phase 2 Study of Nivolumab after CAR-T Failure

While checkpoint inhibition may theoretically improve T-cell effector function following CAR-T failure, a prospective trial of pembrolizumab following CAR-T in non-Hodgkin lymphoma (NHL) showed an ORR of only 25% (Chong Blood 2022). Nivolumab (nivo) has not been studied prospectively in this setting, and the efficacy of post-CAR-T checkpoint inhibition in multiple myeloma (MM) has not been characterized.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Rahul Banerjee, Ryan C Lynch, Qian Vicky Wu, Sylvain Simon, Chaitra S Ujjani, Brian G Till, Natalie Wuliji, Daria Gausman, Joshua Dizon, Mary L. Kwok, Sarah S. Lee, Rebecca W Silbermann, Eva Medvedova, David G. Maloney, Jorge Ramos, Mazyar Shadman, Jordan Tags: 549 Source Type: research